Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.The US Food and Drug Administration (FDA) has approved Sun Pharmaceutical Industries' abbreviated new drug application (ANDA) for Doxorubicin HCl Liposome Injection USP, 2 mg/ml.
Subscribe to our email newsletter
Doxorubicin HCl Liposome Injection USP, 2 mg/ml, which is generic equivalent to Janssen Research and Development’s Doxil Liposome Injection, 2 mg/mL, is indicated for use in patients with ovarian cancer that has progressed or recurred after platinum-based chemotherapy.
Doxorubicin HCl Liposome Injection USP, 2mg/mL will be available in 20 mg/10mL and 50 mg/25mL single-use vials, claims the company.
Sun Pharmaceutical said the application was submitted to the FDA by its subsidiary.